obesity

News

Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.

News

Oura has launched a trial to see if data collected from its smart rings can help scientists understand physiological changes with obesity treatment.

News

Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.

News

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.

News

A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide has been recalled from sale due to sterility concerns.

News

Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.